UW-CTRI has one new study and 9 other active studies. Here are the new studies:
C3I COVID-19 Study. UW-CTRI is joining the quest to better understand COVID-19. The National Cancer Institute has charged researchers from the Cancer Center Cessation Initiative (C3I), coordinated at UW, to learn whether tobacco use is associated with disease severity, complications and/or mortality outcomes among patients with COVID-19. The C3I Coordinating Center is housed at the UW Carbone Cancer Center (UW-CCC) and includes several UW-CTRI staff. It’s led by Principal Investigator Dr. Betsy Rolland and supported by Danielle Pauk, Dr. Heather D’Angelo, Dr. Wei-Yin Loh, Dr. Stevens Smith, Marika Rosenblum, Rob Adsit, Dr. Tim Baker, and Dr. Michael Fiore. For this new COVID initiative, Dr. Doug Jorenby and Dr. Wendy Theobald will join. C3I will select 20 health systems (who are already part of C3I) to participate in this new COVID-19 initiative. Beginning in 2020, the project will collect data in real time on more than 60,000 total inpatients and outpatients who:
- Have a history of smoking or vaping tobacco.
- Test positive for, or are diagnosed with, COVID-19.
- Have electronic health records linked at participating systems.
Data will also be retrospective to February 2020 and continuing to January 2021. The project will track factors such as length of hospitalization, whether they were admitted to intensive care, intubation, ventilation, and mortality. They’ll control for overarching factors such as gender, age and comorbid conditions. C3I and its partners will track data from the participation centers in real time, aiming to answer the question: Does smoking increase risk of adverse outcomes among COVID-19 patients?